Medicines are designed for everyone ,yet the data that supports their safety and efficacy often does not reflect the full diversity of the populations who use them.
For pharmacovigilance (PV), this imbalance presents a critical challenge:
how can safety systems ensure equitable monitoring when not all patient groups are equally represented?
Regulators, industry leaders, and global health agencies are now emphasising the need for diversity, equity, and inclusion (DEI) in both clinical trials and post-marketing safety surveillance. The goal is clear ,to ensure that PV systems protect every patient, not just the majority.
Where Gaps Exist in Drug Safety Data
Despite progress, many PV databases and adverse event reports lack key demographic information.Common challenges include:
- Limited demographic data collected in spontaneous reports or clinical trials.
- Underrepresentation of older adults, pregnant women, children, and minority ethnic groups.
- Cultural and linguistic barriers to adverse event reporting.
- Bias in data capture and analysis, particularly in automated or AI-driven systems.
These gaps make it difficult to detect population-specific safety signals ,potentially delaying recognition of adverse reactions that disproportionately affect certain groups.
The Role of Audits in Promoting Diversity and Inclusion
Pharmacovigilance audits have a vital role to play in ensuring diversity and inclusion are built into safety systems. A DEI-aware audit approach involves assessing how PV systems collect, analyse, and act upon data from all patient populations.
Key audit considerations include:
1. Data Completeness and Quality
Auditors should assess whether PV databases capture key demographic variables such as age, sex, ethnicity, and pregnancy status ,and if missing data are systematically reviewed or addressed.
2. Reporting Accessibility
Audit reviews should determine whether patient reporting systems (web portals, mobile apps, helplines) are accessible to all groups ,including multilingual and disability-friendly options.
3. Bias in Algorithms and AI Tools
With increased use of automation in case processing and signal detection, auditors must check for bias in algorithms, ensuring automated systems don’t inadvertently prioritise or omit certain population data.
4. Cross-Functional Collaboration
Diversity in PV cannot exist in isolation. Auditors should review whether PV teams collaborate with clinical, regulatory, and medical affairs to identify representation gaps and integrate findings into broader safety strategies.
5. Oversight and Continuous Improvement
PV audits should evaluate how organisations monitor their inclusivity metrics over time ,and whether corrective actions are implemented when gaps are identified.
The Regulatory Perspective
Regulatory bodies such as the EMA, FDA, and WHO are encouraging diversity in both data collection and reporting.For example, the FDA’s Diversity Action Plans and the EMA’s guidance on clinical trial inclusion both highlight the importance of demographic balance ,not only during development but also in post-marketing safety monitoring.
This trend indicates that auditors will increasingly need to evaluate diversity and inclusion as part of GVP compliance.
How Q&V Can Help
At Q&V, we recognise that equitable safety monitoring is not only a compliance requirement ,it’s a moral imperative.Our expert auditors and consultants support organisations in:
- Conducting PV audits focused on demographic data completeness and DEI integration.
- Assessing data governance systems to identify and address underrepresentation.
- Evaluating digital and AI-driven PV tools for bias and inclusivity.
- Delivering training on DEI principles in pharmacovigilance and safety management.
We help ensure your PV system reflects the diversity of the patients you serve, building trust, transparency, and stronger global safety outcomes.
Get in touch with Q&V to learn how our audit and compliance services can enhance equity in drug safety.